605507 Stock Overview
Engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Guobang Pharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.86 |
| 52 Week High | CN¥23.09 |
| 52 Week Low | CN¥13.01 |
| Beta | 0.37 |
| 1 Month Change | -1.93% |
| 3 Month Change | 15.44% |
| 1 Year Change | 23.58% |
| 3 Year Change | -26.19% |
| 5 Year Change | n/a |
| Change since IPO | -55.52% |
Recent News & Updates
Recent updates
Guobang Pharma Ltd. (SHSE:605507) Screens Well But There Might Be A Catch
Dec 09
Calculating The Fair Value Of Guobang Pharma Ltd. (SHSE:605507)
Aug 26These 4 Measures Indicate That Guobang Pharma (SHSE:605507) Is Using Debt Extensively
Jul 24Guobang Pharma Ltd. (SHSE:605507) Analysts Just Cut Their EPS Forecasts Substantially
May 21Fewer Investors Than Expected Jumping On Guobang Pharma Ltd. (SHSE:605507)
Apr 18We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt
Mar 25Shareholder Returns
| 605507 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 2.5% | -1.0% | 0.4% |
| 1Y | 23.6% | -3.0% | 12.3% |
Return vs Industry: 605507 exceeded the CN Pharmaceuticals industry which returned -4.4% over the past year.
Return vs Market: 605507 exceeded the CN Market which returned 9.8% over the past year.
Price Volatility
| 605507 volatility | |
|---|---|
| 605507 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 605507 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 605507's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 4,231 | n/a | www.gbgcn.com |
Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. Its products include quinolones, marcolides, cephalosporins, characteristic APIs, preparations and accessories, key pharmaceutical intermediates, mobile protection APIs, kinetophoretic preparations, and feed additives. The company sells its products approximately in 112 countries and regions worldwide.
Guobang Pharma Ltd. Fundamentals Summary
| 605507 fundamental statistics | |
|---|---|
| Market cap | CN¥11.53b |
| Earnings (TTM) | CN¥702.28m |
| Revenue (TTM) | CN¥5.71b |
16.4x
P/E Ratio2.0x
P/S RatioIs 605507 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 605507 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.71b |
| Cost of Revenue | CN¥4.35b |
| Gross Profit | CN¥1.37b |
| Other Expenses | CN¥663.41m |
| Earnings | CN¥702.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.27 |
| Gross Margin | 23.90% |
| Net Profit Margin | 12.29% |
| Debt/Equity Ratio | 11.6% |
How did 605507 perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield24%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 00:28 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guobang Pharma Ltd. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhu Chen | Citic Securities Co., Ltd. |
| Kai Wang | Citic Securities Co., Ltd. |
| Jiarui Lu | Guosen Securities Co., Ltd. |